RxSight Securities Fraud Class Action
Analysis based on 29 articles · First reported Jul 24, 2025 · Last updated Sep 03, 2025
The class action lawsuit against RxSight for alleged securities fraud is expected to negatively impact RxSight's stock price and investor confidence. The legal firms, Levi & Korsinsky and Rosen Law Firm, are actively seeking to represent investors, potentially leading to significant financial recovery for affected shareholders.
RxSight, a publicly traded company, is facing multiple class action lawsuits filed by law firms Levi & Korsinsky and Rosen Law Firm. The lawsuits allege that RxSight made false and misleading statements and/or failed to disclose that it was experiencing 'adoption challenges' and structural issues, leading to declines in sales and utilization. Furthermore, the lawsuits claim that RxSight overstated demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025. Investors who purchased RxSight securities between November 7, 2024, and July 8, 2025, are encouraged to join the class action, with a lead plaintiff deadline of September 22, 2025. The legal actions aim to recover losses for investors who suffered damages due to these alleged securities law violations.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard